The economic consequences
of CINV can be significant
Severe CINV episodes present a significant cost
for national healthcare services 9
Mean cost per patient:
€389 €750 €1,017
Italy France Germany
When patients do not receive guideline-recommended CINV preventative treatment,
healthcare visits due to CINV are higher 1
Prevention is central to effective CINV management
• 32% of healthcare providers
delayed or discontinued a patient’s
chemotherapy because of CINV 10
• International antiemetic guidelines
recommend drug administration targeting
CINV prevention 1
• Guideline compliance can significantly
reduce CINV incidence by almost
10% when compared with guideline-
inconsistent prophylaxis, as reported in
a prospective, observational multicentre
study 1
• Oncologists estimated that 35%
of patients made mistakes
(i.e. missed or delayed doses) during
home administration of antiemetics 11